tiprankstipranks
Trending News
More News >
Hogy Medical Co Ltd (JP:3593)
:3593

Hogy Medical Co (3593) AI Stock Analysis

Compare
1 Followers

Top Page

JP:3593

Hogy Medical Co

(3593)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
¥5,957.00
▼(-9.19% Downside)
Hogy Medical Co's stock score is primarily influenced by its stable financial position and reasonable profitability margins, despite concerns over declining revenue and free cash flow growth. The technical analysis suggests a cautiously optimistic outlook, but the high P/E ratio raises valuation concerns. The absence of recent earnings call insights or notable corporate events limits additional context.
Positive Factors
Strong Equity Position
A strong equity position with low leverage enhances financial stability and reduces insolvency risk, providing a solid foundation for long-term growth.
Profitability Margins
Stable profitability margins indicate efficient cost management and pricing power, which are crucial for sustaining long-term financial health.
Sufficient Operating Cash Flow
Generating sufficient cash from operations ensures the company can meet its financial obligations and reinvest in growth opportunities.
Negative Factors
Declining Revenue Growth
A decline in revenue growth can impact the company's ability to expand and compete, potentially affecting its market position and long-term prospects.
Decline in Free Cash Flow
Reduced free cash flow limits the company's ability to invest in new projects, pay down debt, or return capital to shareholders, impacting future growth.
Low Return on Equity
A low ROE indicates inefficient use of equity capital, which can hinder the company's ability to generate shareholder value and attract investment.

Hogy Medical Co (3593) vs. iShares MSCI Japan ETF (EWJ)

Hogy Medical Co Business Overview & Revenue Model

Company DescriptionHogy Medical Co. (3593) is a prominent player in the healthcare sector, specializing in the development, manufacturing, and distribution of advanced medical devices and diagnostic solutions. The company focuses on providing innovative products that enhance patient care and streamline healthcare processes, catering to hospitals, clinics, and healthcare providers globally. Hogy Medical Co. offers a diverse range of products including surgical instruments, imaging equipment, and patient monitoring systems, aimed at improving clinical outcomes and operational efficiency within the medical field.
How the Company Makes MoneyHogy Medical Co. generates revenue primarily through the sale of its medical devices and diagnostic products, which are distributed to healthcare institutions and practitioners. The company employs a multi-faceted revenue model that includes direct sales, partnerships with distributors, and long-term contracts with healthcare organizations. Key revenue streams include sales from surgical instruments, imaging technologies, and monitoring equipment. Additionally, Hogy Medical Co. may benefit from service agreements and maintenance contracts associated with its products. Strategic partnerships with healthcare providers and technology firms further enhance its market reach and drive sales growth, contributing significantly to its overall earnings.

Hogy Medical Co Financial Statement Overview

Summary
Hogy Medical Co exhibits a stable financial position with strong operational efficiency and a solid balance sheet. However, declining revenue growth and profitability metrics, along with reduced free cash flow, present challenges. The company needs to address these issues to sustain long-term growth and profitability.
Income Statement
65
Positive
Hogy Medical Co's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) gross profit margin is healthy at 32.19%, but the net profit margin has declined to 3.21%, indicating pressure on profitability. Revenue growth has turned negative at -0.89% TTM, reflecting challenges in maintaining sales momentum. EBIT and EBITDA margins are stable, suggesting operational efficiency, but the declining revenue growth is a concern.
Balance Sheet
72
Positive
The balance sheet of Hogy Medical Co is relatively strong with a low debt-to-equity ratio of 0.18 TTM, indicating prudent financial leverage. The return on equity has decreased to 1.67% TTM, reflecting reduced profitability. The equity ratio remains robust, suggesting a solid capital structure, but the declining ROE points to potential profitability challenges.
Cash Flow
58
Neutral
Cash flow analysis reveals a decline in free cash flow growth by -25.12% TTM, indicating potential cash generation issues. The operating cash flow to net income ratio is strong at 0.96 TTM, showing good cash conversion. However, the free cash flow to net income ratio has decreased, highlighting challenges in sustaining free cash flow levels.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue38.38B39.14B39.10B38.98B36.78B36.50B
Gross Profit12.49B12.62B12.49B15.74B15.42B15.33B
EBITDA8.43B8.75B10.71B9.84B10.25B10.18B
Net Income560.00M1.52B2.80B4.32B4.37B4.96B
Balance Sheet
Total Assets94.92B97.89B100.04B102.18B98.97B105.64B
Cash, Cash Equivalents and Short-Term Investments20.28B22.00B19.42B18.86B14.36B20.55B
Total Debt12.67B13.67B5.82B8.89B10.00B330.00M
Total Liabilities21.62B23.56B13.92B18.50B18.97B9.69B
Stockholders Equity73.30B74.32B86.11B83.61B79.96B95.88B
Cash Flow
Free Cash Flow1.41B6.53B4.32B7.78B5.30B-686.00M
Operating Cash Flow6.89B11.76B7.12B9.18B8.50B6.85B
Investing Cash Flow-4.58B-3.92B-3.26B-1.95B-3.81B-6.95B
Financing Cash Flow-3.81B-5.46B-3.89B-3.14B-11.05B-2.50B

Hogy Medical Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6560.00
Price Trends
50DMA
5578.20
Positive
100DMA
5341.23
Positive
200DMA
4751.26
Positive
Market Momentum
MACD
217.23
Negative
RSI
72.71
Negative
STOCH
89.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3593, the sentiment is Positive. The current price of 6560 is above the 20-day moving average (MA) of 5882.50, above the 50-day MA of 5578.20, and above the 200-day MA of 4751.26, indicating a bullish trend. The MACD of 217.23 indicates Negative momentum. The RSI at 72.71 is Negative, neither overbought nor oversold. The STOCH value of 89.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3593.

Hogy Medical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
¥188.97B21.616.47%3.17%1.96%22.78%
73
Outperform
¥142.95B30.782.73%5.10%-26.13%
67
Neutral
¥18.03B12.792.47%8.52%25.85%
66
Neutral
¥166.69B24.395.66%2.67%5.43%-20.67%
59
Neutral
¥141.86B253.340.78%1.33%-2.06%-79.17%
54
Neutral
¥10.65B68.183.90%0.38%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3593
Hogy Medical Co
6,560.00
1,858.14
39.52%
JP:7716
Nakanishi
1,947.00
-388.03
-16.62%
JP:7817
Paramount Bed Holdings Co
3,505.00
847.80
31.91%
JP:3154
Medius Holdings Co., Ltd.
801.00
-16.94
-2.07%
JP:7702
JMS Co., Ltd.
438.00
19.46
4.65%
JP:7730
Mani, Inc.
1,460.00
-247.52
-14.50%

Hogy Medical Co Corporate Events

Hogy Medical Reports Decline in Financial Performance for H1 2025
Oct 27, 2025

Hogy Medical Co., Ltd. reported a decline in its financial performance for the six months ended September 30, 2025, with net sales decreasing by 3.9% and significant drops in operating and ordinary profits. The company’s profit attributable to owners of the parent fell by 51.4% compared to the previous year. Despite the downturn, the company plans to increase its annual dividend per share, indicating confidence in its long-term financial health. The forecast for the fiscal year ending March 31, 2026, shows a slight increase in net sales but continued pressure on profits, reflecting ongoing challenges in the market.

Hogy Medical Revises Earnings Forecasts Amid Business Challenges
Oct 15, 2025

Hogy Medical Co., Ltd. has announced a downward revision of its earnings forecasts for both the interim and full fiscal year ending March 31, 2026, due to recent business performance developments. The revised forecasts indicate significant reductions in net sales, operating profit, ordinary profit, and profit attributable to owners of the parent, reflecting challenges that may impact the company’s financial health and market position.

Hogy Medical Co. Addresses Privatization Speculation
Sep 18, 2025

Hogy Medical Co., Ltd. has been the subject of media reports suggesting its potential privatization, but the company has clarified that no official decision has been made. The company continues to evaluate various strategic options to enhance its corporate value, indicating ongoing considerations but no confirmed plans.

Hogy Medical Revises Shareholder Benefits Amid Product Changes
Sep 17, 2025

Hogy Medical Co., Ltd. has announced a revision to its shareholder benefits program, prompted by the discontinuation of its original calendar production. The revised benefits will no longer include the original calendar but will continue to offer complimentary admission tickets to the Hoki Museum and QUO Cards, along with original design face masks. These changes will be effective for shareholders recorded as of September 30, 2025, with benefits distributed in mid-December. This adjustment reflects the company’s effort to maintain shareholder engagement and satisfaction despite changes in its product offerings.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 11, 2025